Targeting survivin in leukemia

  • Bing Z. Carter | bicarter@mdanderson.org Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, Houston, United States.
  • Michael Andreeff Department of Leukemia, The University of Texas M.D. Anderson Cancer Center and Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, Houston, United States.

Abstract

Survivin, a member of the inhibitors of apoptosis family of proteins, is one of the most frequently upregulated transcripts in solid tumors and hematopoietic malignancies. Survivin’s importance in tumorigenesis is attributed to the fact that it has two functions: to suppress apoptosis and to regulate cell division. The combination of these two functions gives a significant growth and survival advantage on neoplastic cells. This, together with its overexpression in cancer cells, its association with resistance to chemo- and other therapies, and the resulting poor prognosis observed in certain tumors makes survivin a promising target for therapy. In this review, we describe what is currently know about survivin regulation in normal and malignant cells, focusing in particular on the aberrant expression of the protein in leukemia and its possible clinical implications. Various strategies to target survivin will also be described.

Downloads

Download data is not yet available.
Published
2011-12-19
Section
Reviews
Keywords:
Survivin - Leukemia - IAPs - Expression - Targeting
Statistics
Abstract views: 956

FULL TEXT: 222
Share it
How to Cite
Carter, B. Z., & Andreeff, M. (2011). Targeting survivin in leukemia. Oncology Reviews, 1(4), 195-204. Retrieved from https://oncologyreviews.org/index.php/or/article/view/oncol.2007.195